US Bio Company CEO and CFO Realize Hundreds of Millions in Stock Option Gains While Retaining Shares

On April 21 and 22, United Therapeutics Corporation (UTHR) Chairman and CEO Martine Rothblatt exercised stock options to purchase common shares, then sold a substantial portion of them at approximately $564 to $580 per share, securing about $9 million in liquidity (roughly KRW 10 billion). According to the filing, Rothblatt’s direct holdings remained around 40,000 shares, and when factoring in indirect holdings through her spouse and family trusts, she still maintains a significant economic interest.

On April 27, Chief Financial Officer and Treasurer James Edgmon exercised his stock options and sold all the acquired shares, realizing a gain of about $5.7 million (around KRW 7 billion). He still retained a stake in the high ten-thousands of shares after the sale, and all transactions were executed under a pre-established Rule 10b5-1 trading plan.

Recently, the U.S. FDA approved the start of clinical trials for UHeart, a porcine-derived xenogeneic heart, providing new momentum for the company’s pipeline of alternative organ-transplant technologies. On May 6, United Therapeutics reported its first-quarter 2026 financial results and provided updates on its pulmonary arterial hypertension treatments and organ transplant-related initiatives.

United Therapeutics Corporation (UTHR) is a NASDAQ-listed biotech company focused on developing therapies for life-threatening chronic and rare diseases, including pulmonary arterial hypertension, as well as technologies to expand the supply of transplantable organs. Founder and CEO Martine Rothblatt launched the company while seeking a treatment for her daughter’s rare disease and continues to lead bioengineering and xenotransplantation projects aimed at creating alternatives for lungs, livers, and other transplantable organs.